Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
18.92
-2.62 (-12.16%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cidara Therapeutics stock have an average target of 38, with a low estimate of 33 and a high estimate of 46. The average target predicts an increase of 100.85% from the current stock price of 18.92.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cidara Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 2 | 3 | 3 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 5 | 6 | 7 | 7 | 8 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citizens Capital Markets | Citizens Capital Markets | Buy Initiates $46 | Buy | Initiates | $46 | +143.13% | Mar 12, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $35 | Strong Buy | Maintains | $24 → $35 | +84.99% | Mar 10, 2025 |
Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +84.99% | Mar 7, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 27, 2025 |
RBC Capital | RBC Capital | Buy Initiates $34 | Buy | Initiates | $34 | +79.70% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
n/a
from 1.28M
Revenue Next Year
n/a
EPS This Year
-11.63
from -26.75
EPS Next Year
-11.09
from -11.63
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -5.71 | -4.08 | -3.22 | ||
Avg | -11.63 | -11.09 | -10.38 | ||
Low | -17.01 | -18.06 | -18.90 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.